Zhejiang Hisun Pharmaceutical Secures Tentative Selection for Five Products in National Bulk Drug Procurement

Stock News08-03

Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that on July 31, 2026, the company and its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., participated in the bidding process for the 12th round of national centralized drug procurement organized by the Joint Procurement Office. According to the tentative results published by the office that evening, five products within the scope of this procurement are tentatively selected.

The products—Epirubicin Hydrochloride for Injection, Vancomycin Hydrochloride for Injection, Imipenem and Cilastatin Sodium for Injection, Teicoplanin for Injection, and Tacrolimus Capsules—passed generic drug quality and efficacy consistency evaluations in March 2021, November 2021, July 2023, July 2024, and September 2025, respectively.

These tentatively selected products generated combined sales of 426 million yuan in 2025, representing approximately 4.04% of the company's total revenue for that year. The tentative winning prices show a certain decline compared to the average local winning prices from previous rounds. If confirmed, this selection will help expand the domestic sales market for these products, increase market share, further advance the company's formulation business, enhance brand influence, and deliver high-quality, affordable products to the market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134729119?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 15:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134729119","market":"hk","top_or_hot":-1,"title":"Zhejiang Hisun Pharmaceutical Secures Tentative Selection for Five Products in National Bulk Drug Procurement","media":"Stock News","content":"<p><b>Zhejiang Hisun Pharmaceutical Co.,Ltd.</b> (<b>600267.SH</b>) announced that on July 31, 2026, the company and its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., participated in the bidding process for the 12th round of national centralized drug procurement organized by the Joint Procurement Office. According to the tentative results published by the office that evening, five products within the scope of this procurement are tentatively selected.<br><br>The products—Epirubicin Hydrochloride for Injection, Vancomycin Hydrochloride for Injection, Imipenem and Cilastatin Sodium for Injection, Teicoplanin for Injection, and Tacrolimus Capsules—passed generic drug quality and efficacy consistency evaluations in March 2021, November 2021, July 2023, July 2024, and September 2025, respectively.<br><br>These tentatively selected products generated combined sales of 426 million yuan in 2025, representing approximately 4.04% of the company's total revenue for that year. The tentative winning prices show a certain decline compared to the average local winning prices from previous rounds. If confirmed, this selection will help expand the domestic sales market for these products, increase market share, further advance the company's formulation business, enhance brand influence, and deliver high-quality, affordable products to the market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Hisun Pharmaceutical Secures Tentative Selection for Five Products in National Bulk Drug Procurement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Hisun Pharmaceutical Secures Tentative Selection for Five Products in National Bulk Drug Procurement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-03 15:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Zhejiang Hisun Pharmaceutical Co.,Ltd.</b> (<b>600267.SH</b>) announced that on July 31, 2026, the company and its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., participated in the bidding process for the 12th round of national centralized drug procurement organized by the Joint Procurement Office. According to the tentative results published by the office that evening, five products within the scope of this procurement are tentatively selected.<br><br>The products—Epirubicin Hydrochloride for Injection, Vancomycin Hydrochloride for Injection, Imipenem and Cilastatin Sodium for Injection, Teicoplanin for Injection, and Tacrolimus Capsules—passed generic drug quality and efficacy consistency evaluations in March 2021, November 2021, July 2023, July 2024, and September 2025, respectively.<br><br>These tentatively selected products generated combined sales of 426 million yuan in 2025, representing approximately 4.04% of the company's total revenue for that year. The tentative winning prices show a certain decline compared to the average local winning prices from previous rounds. If confirmed, this selection will help expand the domestic sales market for these products, increase market share, further advance the company's formulation business, enhance brand influence, and deliver high-quality, affordable products to the market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"","article_id":"1134729119","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134729119","pubTimestamp":1785743637,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that on July 31, 2026, the company and its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., participated in the bidding process...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600267":"海正药业","BK0188":"融资融券","BK0060":"抗癌","BK0239":"医药制造","BK0028":"国家队"},"translate_title":"浙江海正药业在国家药品带量采购中获得五个产品的初步中选","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600267":1},"content_text":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that on July 31, 2026, the company and its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., participated in the bidding process for the 12th round of national centralized drug procurement organized by the Joint Procurement Office. According to the tentative results published by the office that evening, five products within the scope of this procurement are tentatively selected.The products—Epirubicin Hydrochloride for Injection, Vancomycin Hydrochloride for Injection, Imipenem and Cilastatin Sodium for Injection, Teicoplanin for Injection, and Tacrolimus Capsules—passed generic drug quality and efficacy consistency evaluations in March 2021, November 2021, July 2023, July 2024, and September 2025, respectively.These tentatively selected products generated combined sales of 426 million yuan in 2025, representing approximately 4.04% of the company's total revenue for that year. The tentative winning prices show a certain decline compared to the average local winning prices from previous rounds. If confirmed, this selection will help expand the domestic sales market for these products, increase market share, further advance the company's formulation business, enhance brand influence, and deliver high-quality, affordable products to the market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134729119","isCrawlerRequest":true}